EGFR and head and neck squamous cell carcinoma: Study demonstrated that Nanobody-albumin nanoparticles (NANAPs) coated with bifunctional polyethylene glycol 3500 (PEG) and functionalized with anti-EGFR nanobody (EGa1) to delivery of a multikinase inhibitor17864-Lx- a platinum-bound sunitinib analogue- are able to increase binding 40-fold in EGFR positive HNSCC -14C cells (14C) compared to nanoparticles without EGa1 (144).